MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Follow-Up Questions
Who is the CEO of Mediwound Ltd?
Mr. Ofer Gonen is the Chief Executive Officer of Mediwound Ltd, joining the firm since 2003.
What is the price performance of MDWD stock?
The current price of MDWD is $17.25, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Mediwound Ltd?
Mediwound Ltd belongs to Pharmaceuticals industry and the sector is Health Care
What is Mediwound Ltd market cap?
Mediwound Ltd's current market cap is $187.6M
Is Mediwound Ltd a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for Mediwound Ltd, including 3 strong buy, 8 buy, 1 hold, 0 sell, and 3 strong sell
